What Our Analysts Know About Prometheus Biosciences

By Chris Stiles • Wednesday, December 07 12:10 • Permanent Link

Prometheus Biosciences logged a 173.9% change during today's afternoon session, and is now trading at a price of $98.78 per share. The S&P 500 index moved -0.1% and the Dow Industrial Average posted a -0.5% change. RXDX's trading volume is 6,358,303 compared to the stock's average volume of 597,593.

Prometheus Biosciences trades 53.92% away from its average analyst target price of $64.18 per share. The 11 analysts following the stock have set target prices ranging from $55 to $75, and on average have given Prometheus Biosciences a rating of strong_buy.

If you are considering an investment in RXDX, you'll want to know the following:

Prometheus Biosciences has moved 7.6% over the last year, and the S&P 500 logged a change of -16.2%
Based on its trailing earning per share of -2.78, Prometheus Biosciences has a trailing 12 month Price to Earnings (P/E) ratio of -35.6 while the S&P 500 average is 15.97
RXDX has a forward P/E ratio of -27.0 based on its forward 12 month price to earnings (Eps) is $-3.66 per share
Its Price to Book (P/B) ratio is 17.8 compared to its sector average of 4.07
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD).
Based in San Diego, the company has 72 full time employees and a market cap of $4,143,260,416.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.